Lainie P. Martin, MD
- Request Appointment
- Clinical Locations
- Education, Training & Credentials
- Patient Stories
- Research Profile
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Chief, Gynecologic Medical Oncology
Patient education is a priority because an informed patient can make the best treatment decisions. Patients who understand their disease and know what to expect throughout their treatment can reduce some of the fears associated with a diagnosis of cancer. Rather than dictating treatment, I treat each patient as an individual. For example, some patients prefer a more aggressive plan, while others decide to take a more conservative course of treatment. It is very important for patients to participate in making the treatment decisions that are best for them.
The clinical trials available at Fox Chase give patients access to more treatment options and the hope of improving cancer treatment for future patients. I have a special interest in targeted-therapies, which have become important to the future of cancer treatment. These therapies have the potential to reduce toxic side effects and improve control of disease.
There are many questions yet to be answered about the causes of cancer and more effective treatments are needed. Here at Fox Chase Cancer Center, we have been working in the laboratory and in the clinic to find more effective treatments and to advance cancer care. It is a privilege to participate in this effort and to work for and with my patients to provide them with the best care available. Collapse
- Fellow, Hematology/Oncology, Fox Chase Cancer Center and Temple University, Philadelphia, PA
- Resident, Internal Medicine, Boston University Medical Center, Boston, MA
- MD, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 1999
- American Board of Internal Medicine
- Medical Oncology
- National Comprehensive Cancer Network (NCCN)
- Ovarian Cancer Panel
- American Association for Cancer Research (AACR)
- American College of Physicians
- American Medical Association
- American Medical Women's Association
- American Society of Clinical Oncology
- Genomic Advisory Board/Cancer Genome Institute (CGI) Advisory Committee, Fox Chase Cancer Center
In May 2005, Jeff Lambert, 34, went to his family doctor to have a suspicious mole removed from his right shoulder. Within a few days, Jeff got the call no one wants – he had melanoma, the most aggressive type of skin cancer. “When we hung up, I called Fox Chase Cancer Center right away,” says Jeff, who lives in Allentown, PA, about 60 miles north of Fox Chase. “I was terrified, but from my first call I was met with care, courtesy, and professionalism.”
Tanya Dwyer was treated in 2004 for a rare type of cancer affecting younger women, called choriocarcinoma, in Philadelphia. Choriocarcinomas usually occur in the reproductive organs and develop from cells that would typically turn into eggs in a woman's uterus. These cells usually grow quickly and spread widely.
Tanya was a single working mom at the time. "Then, several years later, I found out the cancer had recurred in my lung," she recalled. "I was devastated."
When Cathy Van Horn met with her Fox Chase Cancer Center team in 2012, she knew where things stood. “I understood that my cancer wasn’t going to be cured. The best we could do was to manage my cancer and keep it at bay. The longer we could stay positive and keep moving forward, the longer I’d be here.”
Like most people, Cindy Danko had no time to be sick. A full time house painter, Cyd – as she’s known to her friends – was used to keeping a busy schedule packed with physically demanding work. In February 2009, shortly before her 50th birthday, Cyd went to her gynecologist for an annual exam. Within a few days, her doctor called to explain that her Pap test was abnormal. “I thought it was a mistake,” said Cyd.
- Investigative Therapy
Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008 Mar 1;14(5):1291-5. PubMed. Review.
Martin L, Schilder R. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. J Clin Oncol. 2007 Jul 10;25(20):2894-901. PubMed